Alzheimer’s Research Program Transforming Care Award
ID: 358721Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358721
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Care Award to support innovative clinical research aimed at improving care for individuals with Alzheimer's disease and related dementias (AD/ADRD). This funding opportunity encourages community collaboration and requires projects to focus on interventions that enhance the quality of life for both patients and their caregivers. Approximately $5.2 million is available to fund around three awards, with pre-applications due by June 12, 2025, and full applications due by August 29, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    FY25.pdf
    The Fiscal Year 2025 Department of Defense Alzheimer’s Research Program (AZRP) outlines various award mechanisms aimed at advancing research on Alzheimer's disease and related dementias (AD/ADRD) and traumatic brain injury (TBI). Three primary awards are detailed: the Transforming Diagnosis Award, the Transforming Research Award, and the Transforming Care Award. Each award supports innovative studies that require community collaboration and prohibits clinical trials while allowing the use of existing data. The Transforming Diagnosis Award, with a maximum funding limit of $1.5M for the base option and $1.7M for career initiation or transition (CIT), focuses on enhancing diagnostic methods for AD/ADRD. The Transforming Research Award, limited to $1.0M, aims to mitigate risks and improve patient care through transformative research. The Transforming Care Award emphasizes person-centered research, allowing clinical trials, with funding up to $1.6M and $1.8M for CIT. All three awards require preliminary data submission, a pre-proposal for invited applications, and adherence to community collaboration. Submission deadlines for pre-proposals and applications fall on June 12, 2025, and August 29, 2025, respectively. This initiative underscores the federal commitment to improving outcomes for military personnel affected by AD/ADRD and TBI through strategic research support.
    HT942525AZRPTrCA.pdf
    The Department of Defense’s FY25 Alzheimer’s Research Program is announcing the availability of funding for the Transforming Care Award, aimed at supporting innovative research focused on improving care for individuals with Alzheimer’s disease and related dementias. The program encourages applications from a diverse range of eligible organizations, including for-profit and non-profit entities, with a special emphasis on community collaboration. Approximately $5.2 million is allocated to fund around three awards, with specific cost caps depending on the type of application (single PI or partnership). Pre-applications are due by June 12, 2025, followed by a full application deadline of August 29, 2025. Successful projects should demonstrate innovative approaches to address caregiver burden, improve quality of life, and incorporate community perspectives. The awards can last up to four years and will finalize funding decisions by September 2026. A two-step application process requires initial pre-proposals, which must include a narrative outlining the research's significance and impact, followed by a comprehensive full application for those invited. Review criteria will assess the project’s impact, feasibility, strategy, and integration of community collaboration, ensuring that research meets the needs of those affected by Alzheimer's and related conditions. This initiative reflects a commitment to advance care and support for a vulnerable population while fostering cross-disciplinary cooperation.
    Similar Opportunities
    Dementia Care and Caregiver Support Intervention Research - Stages II - V
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for research applications focused on developing behavioral interventions for individuals living with Alzheimer's disease and related dementias, as well as their caregivers. This initiative aims to support a milestone-driven planning phase lasting up to two years, with the potential for transition to a clinical trial phase upon successful completion of the required milestones. The funding opportunity is particularly significant as it addresses critical health challenges associated with aging and dementia care. Interested small businesses are encouraged to prepare for this opportunity, with the estimated synopsis posting date set for November 1, 2025, and applications expected to close by February 16, 2026. For further inquiries, potential applicants can contact Dr. Melissa Riddle at melissa-riddle@nih.gov or by phone at 301-480-6761.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) to support the preclinical and early-stage clinical development of innovative drug candidates aimed at preventing or treating Alzheimer's disease (AD). This funding opportunity focuses on activities such as medicinal chemistry, pharmacokinetics, formulation development, and initial Phase I clinical testing, addressing the urgent public health challenge posed by AD, which currently affects approximately 6.7 million individuals in the U.S. Eligible applicants include a diverse range of organizations, with a funding ceiling of $1.5 million per year, and the application process is set to begin in January 2025, with a closing date of November 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies. Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards. The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Dementia Care and Caregiver Support Intervention Research - Stage I Only
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity titled "Dementia Care and Caregiver Support Intervention Research - Stage I Only," aimed at supporting research focused on developing behavioral interventions for individuals living with Alzheimer's disease and related dementias, as well as their caregivers. This initiative will utilize the R34 activity code and is designed to facilitate the development, modification, and refinement of principle-based behavioral interventions, ensuring their acceptability and feasibility in preparation for later-stage clinical trials. Interested small businesses are encouraged to begin forming collaborations and developing project proposals, with the estimated synopsis posting date on November 1, 2025, and a closing date for applications expected by February 16, 2026. For further inquiries, potential applicants can contact Melissa Riddle, Ph.D., at melissa-riddle@nih.gov or by phone at 301-480-6761.
    Alzheimer's Disease Programs Initiative (ADPI) - State and Community Grant Program
    Administration for Community Living
    The Administration for Community Living is offering the Alzheimer's Disease Programs Initiative (ADPI) - State and Community Grant Program, aimed at enhancing dementia-capable home and community-based service systems. This opportunity includes two application options: Grants to States, which focus on creating and sustaining state-level dementia-capable systems, and Grants to Communities, which support community-based organizations in addressing specific service gaps for individuals living with Alzheimer's disease and related dementias. With an estimated total program funding of $10 million, the program anticipates awarding 12 grants, with individual awards ranging from $850,000 to $1 million. Interested applicants can find more information and contact Kari Benson at aoa.oaa@acl.hhs.gov or by phone at 202-795-7389, with applications due by March 17, 2026.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.